Purification of O-specific polysaccharide from lipopolysaccharide produced by Salmonella enterica serovar Paratyphi A

Vaccine

Volumn 32, Issue 21, 2014, Pages 2457-2462

  Kothari, Sudeep ^a,c   Kim, Jeong Ah ^a   Kothari, Neha ^a   Jones, Christopher ^b   Choe, Woo Seok ^c   Carbis, Rodney ^a  

^a International Vaccine Institute   (South Korea)

^b National Institute for Biological Standards and Control   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

Enteric fever vaccine; O specific polysaccharide; Polysaccharide purification; Salmonella Paratyphi; Vaccine production

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; DEOXYCHOLATE SODIUM; ENDOTOXIN; LIPID A; O SPECIFIC POLYSACCHARIDE; UNCLASSIFIED DRUG;

ACID PRECIPITATION; ARTICLE; BACTERIAL CELL; BACTERIAL MEMBRANE; BACTERIAL STRAIN; DETOXIFICATION; DIAFILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; MEMBRANE FILTER; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PURIFICATION; QUALITY CONTROL; SALMONELLA ENTERICA; SALMONELLA PARATYPHI; SALMONELLA TYPHIMURIUM; ULTRAFILTRATION;

ENTERIC FEVER VACCINE; O-SPECIFIC POLYSACCHARIDE; POLYSACCHARIDE PURIFICATION; SALMONELLA PARATYPHI; VACCINE PRODUCTION;

ACETYLATION; BIOREACTORS; FERMENTATION; FILTRATION; HYDROLYSIS; LIPID A; LIPOPOLYSACCHARIDES; O ANTIGENS; SALMONELLA PARATYPHI A; TECHNOLOGY, PHARMACEUTICAL;

EID: 84898416499     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.02.090     Document Type: Article

References (19)

1. Sahastrabuddhe S., Carbis R., Wierzba T.F., Ochiai R.L. Increasing rates of Salmonella Paratyphi A and the current status of its vaccine development. Expert Rev Vaccines 2013, 12(9):1021-1031.
2. Ochiai R.L., Wang X.Y., von Seidlein L., Yang J., Bhutta Z.A., Bhattacharya S.K., et al. Salmonella Paratyphi A rates, Asia. Emerg Infect Dis 2005, 11:1764-1766.
3. Dong B.Q., Yang J., Wang X.Y., Gong J., von Seidlein L., Wang M.L., et al. Trends and disease burden of enteric fever in Guangxi province, China, 1994-2004. Bull WHO 2010, 88:689-696.
4. Kulkarni S.V., Narayan A., Indumathi V.A., Rao T.S., Kempegowda P. Salmonella Paratyphi A in India-changing trends in presentation and antibiotic susceptibility. Asian J Med Sci 2011, 2:14-17.
5. Typhoid vaccines WHO position paper. Weekly epidemiological record no. 6 2008, 83:49-60. WHO, Geneva, Switzerland.
6. An S.J., Yoon Y.K., Kothari S., Kothari N., Kim J.A., Lee E., et al. Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity. Vaccine 2011, 29(44):7618-7623.
7. 197 conjugates against Salmonella Paratyphi A. PLoS One 2012, 7(11):1-14.
8. Hellerqvist C.G., Lindberg B., Samuelsson K., Lindberg A.A. Structural studies on the O-specific side-chains of the cell-wall lipopolysaccharide from Salmonella Paratyphi A var. durazzo. Acta Chem Scand 1971, 25:955-961.
9. Konadu E., Shiloach J., Bryla D.A., Robbins J.B., Szu S.C. Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella Paratyphi A bound to tetanus toxoid, with emphasis on the role of O acetyls. Infect Immun 1996, 64(7):2709-2715.
10. Micoli F., Rondini S., Gavini M., Pisini I., Lanzilao L., Colucci A.M., et al. A scalable method for O-antigen purification applied to various Salmonella serovars. Anal Biochem 2012, 434:136-145.
11. Jang H., Yoon Y.K., Kim J.A., Kim H.S., An S.J., Seo J.H., Cui C., Carbis R. Optimization of Vi capsular polysaccharide production during growth of Salmonella enteric serotype Typhi Ty2 in a bioreactor. J Biotechnol 2008, 135(1):71-77.
12. Hestrin S. The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application. J Biol Chem 1949, 180(1):249-261.
13. WHO Requirements for Vi polysaccharide typhoid vaccine. WHO technical reports series, no. 840 1994, WHO, Geneva, Switzerland.
14. Jones C. Revised structures for the capsular polysaccharides from Staphylococcus aureus Types 5 and 8, components of novel glycoconjugate vaccines. Carbohydr Res 2005, 340:1097-1106.
15. Lemercinier X., Whitley C., Jones C. Full NMR assignments and revised structure for the repeating unit of the capsular polysaccharide from Streptococcus pneumoniae Type 17F. Carbohydr Res 2000, 325:192-201.
16. Munford R.S., Hall C.L., Rick P.D. Size heterogeneity of Salmonella typhimurium lipopolysaccharides in outer membranes and culture supernatant membrane fragments. J Bacteriol 1980, 144(2):630-640.
17. Mattsby-Baltzer I., Lindgren K., Lindholm B., Edebo L. Endotoxin shedding by enterobacteria: free and cell-bound endotoxin differ in Limulus activity. Infect Immun 1991, 59(2):689-695.
18. Guo Y-Y., Anderson R., McIver J., Gupta R.K., Siber G.R. A simple and rapid method for measuring unconjugated capsular polysaccharide (PRP) of Haemophilus influenza type b in PRP-tetanus toxoid conjugate vaccine. Biologicals 1998, 26:33-38.
19. Kothari S., Kothari N., Kim J.A., Lee E., Yoon Y.K., An S.J., Jones C., Choe W.S., Carbis R. A novel method for purification of Vi capsular polysaccharide produced by Salmonella enterica subspecies enterica serovar Typhi. Vaccine 2013, 31:4714-4719.